SCHEMBL2944717

SCHEMBL2944717

CCC(C)C(CC)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACE P12821 3/20 0.46
ALDH1A1 P00352 1/20 0.43
MME P08473 2/20 0.42
CPA1 P15085 2/20 0.42
ACE2 Q9BYF1 2/20 0.42
TDP1 Q9NUW8 2/20 0.42
CHRM1 P11229 1/20 0.42
AKR1A1 P14550 1/20 0.42
CHRM3 P20309 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
ADRA1A P35348 1/20 0.42
HRH1 P35367 1/20 0.42
DRD3 P35462 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
SLC1A3 P43003 1/20 0.39
SLC1A2 P43004 1/20 0.39
SLC1A1 P43005 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25847046 1.00 ACE (0.46) ACEALDH1A1MMECPA1ACE2
SCHEMBL27984989 1.00 ACE (0.46) ACEALDH1A1MMECPA1ACE2
SCHEMBL13040584 1.00 ACE (0.46) ACEALDH1A1MMECPA1ACE2
SCHEMBL12260419 1.00 ACE (0.46) ACEALDH1A1MMECPA1ACE2
SCHEMBL7334665 0.87 ALDH1A1 (0.39) ACEALDH1A1MMECPA1ACE2
SCHEMBL11369383 0.87 ALDH1A1 (0.39) ACEALDH1A1MMECPA1ACE2
SCHEMBL5929829 0.86 ACE (0.53) ACEALDH1A1MMECPA1ACE2
SCHEMBL11365181 0.84 TDP1 (0.39) ACEALDH1A1MMECPA1ACE2
SCHEMBL30751934 0.84 ALDH1A1 (0.45) ACEALDH1A1MMECPA1ACE2
SCHEMBL18313246 0.84 ACE (0.43) ACEALDH1A1MMECPA1ACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1747183-B1 METHOD OF PREPARING ALKOXYLATION CATALYSTS AND THEIR USE IN ALKOXYLATION PROCESSES HARCROS CHEMICALS INC (US) 2018-06-06 EP claimed
EP-1653937-B1 COMPOUNDS USEFUL FOR TREATING NEUROPATHIC PAIN AND MIGRAINE YISSUM RES DEV CO (IL) 2010-01-06 EP claimed
US-20090182048-A1 Compounds Useful For Treating Neurological Disorders YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2009-07-16 US claimed
EP-1653937-A1 COMPOUNDS USEFUL FOR TREATING NEUROLOGICAL DISORDERS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-05-10 EP claimed
US-20060004098-A1 Compounds useful for treating neurological disorders YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2006-01-05 US claimed
WO-2005009430-A1 COMPOUNDS USEFUL FOR TREATING NEUROLOGICAL DISORDERS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 2005-02-03 WO claimed
EP-0522465-B1 A process for the preparation of an alkyl vinyl ether/maleic anhydride copolymer DAICEL CHEM (JP) 1997-04-16 EP claimed
CN-116659004-B Air conditioner DAIKIN INDUSTRIES, LTD. (JP) 2026-05-26 CN disclosed
EP-4641061-A1 OIL-WELL METAL PIPE NIPPON STEEL CORPORATION (JP) 2025-10-29 EP disclosed
CN-114656934-B Refrigerant circulation device 大金工业株式会社 2024-07-05 CN disclosed
CN-114051525-B Refrigerant-containing composition, use thereof, refrigerator having the composition, method for operating the refrigerator, and refrigeration cycle device having the refrigerator 大金工业株式会社 2024-07-02 CN disclosed
WO-2024135464-A1 OIL-WELL METAL PIPE 日本製鉄株式会社 2024-06-27 WO disclosed
CN-113993973-B Refrigerant-containing composition, use thereof, refrigerator having the composition, method for operating the refrigerator, and refrigeration cycle device having the refrigerator 大金工业株式会社 2024-04-23 CN disclosed
EP-1051461-A2 FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE ORR, William C. (US) 2000-11-15 EP disclosed
WO-1999067199-A1 2-FLUORO-2-ALKYL ALKANOAMIDES WITH ANTICONVULSANT ACTIVITY AMERICAN BIOGENETIC SCIENCES INC. (US) 1999-12-29 WO disclosed
WO-1999066009-A2 FUEL COMPOSITIONS EMPLOYING CATALYST COMBUSTION STRUCTURE ORR WILLIAM C (US) 1999-12-23 WO disclosed
EP-0833879-A1 VAPOR PHASE COMBUSTION METHOD AND COMPOSITIONS II ORR, William C. (US) 1998-04-08 EP disclosed
EP-0763079-A1 VAPOR PHASE COMBUSTION METHODS AND COMPOSITIONS ORR, William C. (US) 1997-03-19 EP disclosed
WO-1996040844-A1 VAPOR PHASE COMBUSTION METHOD AND COMPOSITIONS II ORR WILLIAM C (US) 1996-12-19 WO disclosed
WO-1995033022-A1 VAPOR PHASE COMBUSTION METHODS AND COMPOSITIONS ORR WILLIAM C (US) 1995-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004098-A1 Compounds useful for treating neurological disorders GAP43, CLN6, NLN ACE 3288/4885ALDH1A1 1097/4885MME 615/4885
US-20090182048-A1 Compounds Useful For Treating Neurological Disorders GAP43, CLN6, NLN ACE 3288/4885ALDH1A1 1097/4885MME 615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.